NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
Clinical Trials
51 trialsNCT03853109 2025-07-20
AMG 404 in Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT04882917 2025-03-07
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono
Phase 1 Completed
NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT04727554 2025-01-06
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT05394350 2024-11-08
MK-1088-002
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT04068519 2024-10-26
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
Phase 1/2 Completed
NCT02516813 2024-10-15
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono
Phase 1 Completed
NCT02994953 2024-09-20
COMBO
EMD Serono
Phase 1 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT02261285 2024-05-06
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT03954704 2023-11-21
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT01773421 2023-06-22
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT02197572 2023-01-23
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04049617 2022-10-06
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT02880371 2022-06-16
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT02734433 2022-04-25
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03348514 2021-12-03
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
Phase 1 Completed
NCT03497429 2021-11-09
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT03991494 2021-09-27
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
BeiGene
Phase 1 Completed
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01433991 2021-06-08
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Eisai Inc.
Phase 1/2 Terminated
NCT01693562 2021-05-13
A Phase 1/2 Study to Evaluate MEDI4736
MedImmune LLC
Phase 1/2 Completed
NCT02281409 2021-04-23
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02997176 2021-02-25
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
Phase 1 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT02253992 2020-10-05
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01781429 2020-03-20
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
BioMed Valley Discoveries, Inc
Phase 1/2 Completed
NCT00747474 2019-11-18
Phase I Study of Intravenous LipotecanĀ® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Taiwan Liposome Company
Phase 1 Completed
NCT03065023 2019-07-30
MK-4621-001
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00962091 2019-03-12
Study of MLN8237 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02179918 2019-02-08
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Pfizer
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00635778 2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00632424 2016-03-10
Phase 1 Trial of Oral Ixabepilone
R-Pharm
Phase 1 Terminated
NCT01004822 2015-11-20
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00932126 2015-10-28
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00557856 2015-10-19
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01005355 2014-06-18
Study of IMC-1121B in Patients With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00842335 2013-06-24
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
Jubilant Innovation Ltd.
Phase 1/2 Completed
NCT01469052 2012-03-26
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Pfizer
Phase 1 Completed